1. Academic Validation
  2. A potent inhibitor of osteoclastic bone resorption within a highly conserved pentapeptide region of parathyroid hormone-related protein; PTHrP[107-111]

A potent inhibitor of osteoclastic bone resorption within a highly conserved pentapeptide region of parathyroid hormone-related protein; PTHrP[107-111]

  • Endocrinology. 1991 Dec;129(6):3424-6. doi: 10.1210/endo-129-6-3424.
A J Fenton 1 B E Kemp R G Hammonds Jr K Mitchelhill J M Moseley T J Martin G C Nicholson
Affiliations

Affiliation

  • 1 Dept of Medicine, University of Melbourne, Geelong Hospital, Victoria, Australia.
Abstract

We have recently shown that a carboxyl-terminal sequence of parathyroid hormone-related protein, PTHrP[107-139], is a potent direct inhibitor of osteoclastic bone resorption. We now report that this bone resorption inhibitory activity, which we have called osteostatin, is entirely contained within the highly conserved pentapeptide PTHrP[107-111]. Our results indicate that processing at residue 106 and a free amino terminus is required for full activity of the peptide. The retroinverted peptide is considerably less potent than the parent peptide. The retention of full biological activity in such a short fragment was unexpected. This data provides the basis for the development of further analogs with potential therapeutic use in disorders associated with increased osteoclastic bone resorption.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P4684
    Osteoclastic bone resorption inhibitor